Pfizer Inc. (NYSE:PFE) – Research analysts at Jefferies Group boosted their FY2018 earnings per share estimates for shares of Pfizer in a research report issued to clients and investors on Tuesday. Jefferies Group analyst J. Holford now expects that the biopharmaceutical company will post earnings per share of $2.90 for the year, up from their prior estimate of $2.77. Jefferies Group has a “Neutral” rating and a $40.00 price objective on the stock.
Other equities research analysts also recently issued research reports about the company. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research report on Wednesday. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 31st. Deutsche Bank set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. JPMorgan Chase & Co. set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research report on Wednesday, December 27th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $38.94.
Shares of Pfizer (NYSE:PFE) traded down $0.05 during trading hours on Thursday, hitting $36.94. The stock had a trading volume of 29,396,174 shares, compared to its average volume of 18,624,660. Pfizer has a one year low of $30.90 and a one year high of $37.37. The firm has a market cap of $220,190.00, a P/E ratio of 22.66, a PEG ratio of 2.31 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the prior year, the firm earned $0.61 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year.
Several hedge funds and other institutional investors have recently bought and sold shares of PFE. HL Financial Services LLC increased its position in Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after buying an additional 35,744 shares during the last quarter. Hartford Financial Management Inc. boosted its holdings in Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 835 shares during the period. Cadence Bank NA boosted its holdings in Pfizer by 1.4% during the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 1,428 shares during the period. Majedie Asset Management Ltd boosted its holdings in Pfizer by 7.9% during the second quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after acquiring an additional 24,531 shares during the period. Finally, Stanley Laman Group Ltd. boosted its holdings in Pfizer by 373.7% during the second quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after acquiring an additional 90,160 shares during the period. 69.75% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,450 shares of company stock worth $1,065,220. Company insiders own 0.06% of the company’s stock.
Pfizer announced that its board has initiated a share buyback plan on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.68%. The ex-dividend date is Thursday, February 1st. Pfizer’s payout ratio is 78.53%.
TRADEMARK VIOLATION NOTICE: “FY2018 Earnings Estimate for Pfizer Inc. (PFE) Issued By Jefferies Group” was posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thestockobserver.com/2018/01/19/fy2018-earnings-estimate-for-pfizer-inc-pfe-issued-by-jefferies-group.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.